Patents by Inventor Alistair Ian Longshaw

Alistair Ian Longshaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitor of p38 MAP kinase
    Patent number: 11634406
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: April 25, 2023
    Assignee: RESPIVERT LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Pyrazolyl-ureas as kinase inhibitors
    Patent number: 11142515
    Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 12, 2021
    Assignee: Respivert Limited
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20210179584
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Application
    Filed: September 24, 2020
    Publication date: June 17, 2021
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Inhibitor of p38 MAP kinase
    Patent number: 10815217
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: October 27, 2020
    Assignee: Respivert Ltd.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
    Patent number: 10813932
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: October 27, 2020
    Assignee: Respivert Limited
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors
    Patent number: 10738032
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: August 11, 2020
    Assignee: Respivert Limited
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • PYRAZOLYL-UREAS AS KINASE INHIBITORS
    Publication number: 20200002311
    Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 2, 2020
    Inventors: Alistair Ian LONGSHAW, Euan Alexander Fraser FORDYCE, Stuart Thomas ONIONS, John KING-UNDERWOOD, Jennifer Diane VENABLE, lain WALTERS
  • 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS
    Publication number: 20190192515
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 27, 2019
    Inventors: Kazuhiro ITO, Catherine Elisabeth CHARRON, John KING-UNDERWOOD, Stuart Thomas ONIONS, Alistair Ian LONGSHAW
  • 1-PYRAZOLYL-3- (4- ((2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- I - YL) UREAS AS P38 MAPKINASE INHIBITORS
    Publication number: 20190185458
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 20, 2019
    Inventors: Kazuhiro ITO, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • Pyrazolyl ureas as kinase inhibitors
    Patent number: 10294216
    Abstract: There are provided compounds of formula (I) shown below as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 21, 2019
    Assignee: RESPIVERT LIMITED
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors
    Patent number: 10266519
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: April 23, 2019
    Assignee: RESPIVERT LIMITED
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20190092752
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Application
    Filed: July 11, 2018
    Publication date: March 28, 2019
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
    Patent number: 10238658
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: March 26, 2019
    Assignee: RESPIVERT LIMITED
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • Inhibitor of p38 map kinase
    Patent number: 10045980
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: August 14, 2018
    Assignee: Respivert Ltd
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS
    Publication number: 20180207158
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
    Patent number: 9993478
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 12, 2018
    Assignee: Respivert, Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • 1-PYRAZOLYL-3- (4- ((2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- I - YL) UREAS AS P38 MAPKINASE INHIBITORS
    Publication number: 20180134687
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 17, 2018
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • PYRAZOLYL UREAS AS KINASE INHIBITORS
    Publication number: 20180118719
    Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
  • 3-hydroxypyrrolidine inhibitors of 5?-methylthioadenosine phosphorylase and nucleosidase
    Patent number: 9957272
    Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: May 1, 2018
    Assignees: Victoria Link Limited, Albert Einstein College of Medicine, Inc.
    Inventors: Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
  • Pyrazolyl-ureas as kinase inhibitors
    Patent number: 9884845
    Abstract: There are provided compounds of formula (I) as defined in the specification, which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: February 6, 2018
    Assignee: Respivert Limited
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters